July 2026EpilepsyGTx appoints Dr Teresa Nunes as Chief Medical Officer• Appointment of senior clinical leader will support progression of lead candidate EPY201 through the clinic … London, UK…Read more
July 2026EpilepsyGTx partners with ClearPoint Neuro to support targeted delivery of lead gene therapy in epilepsy• ClearPoint Neuro’s system enables precise delivery to the seizure focus, ensuring best possible efficacy and safety of…Read more
April 2026EpilepsyGTx appoints Professor Dimitri Kullmann as Chief Scientific Officer• Appointment of UCL Neurologist will accelerate the delivery of novel gene therapies for refractory epilepsy … London, UK…Read more
December 2025EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy• Investment from XGEN Venture, British Business Bank, and a global biopharmaceutical company will support first-in-human…Read more
June 2024EpilepsyGTx announces a $10M fundraise to complete the CTA-enabling nonclinical package for lead program EPY201London, UK, June 24, 2024 … EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene…Read more
June 2024EpilepsyGTx announces completion of the large animal biodistribution studies supporting lead program EPY201London, UK, June 10, 2024 … EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene…Read more